Vitrafy Life Sciences Limited (ASX:VFY)
Australia flag Australia · Delayed Price · Currency is AUD
2.550
+0.250 (10.87%)
Nov 16, 2026, 4:10 PM AEDT
← View all transcripts

Earnings Call: Q1 2027

Oct 27, 2026

Summary

Quarter-end cash was AUD 38.3 million, with funding expected to last into calendar 2028. Partnerships expanded across blood and cell and gene therapy, while management remains on track for a year-end U.S. device listing, subject chiefly to blood supply for validation.

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

Sweet. The only thing with the screen share function, I lose visual. I can only see the PowerPoint. Just note that I will not be able to see anything except for the display screen on the PowerPoint itself.

Operator

Right.

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

Tim S is sitting next to me. If he just waves his arm. If something is up, just wave your arm and I will pause.

Operator

You are going to be flipping the slides then, Brent. Yeah, great.

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

No problems with that.

Operator

Adrian, just in the past, have you had a bunch of questions from the attendees in the past or?

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

We usually get half a dozen in the chat.

Operator

Okay.

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

It is usually a flow. You start with one, then once the first one gets asked, you get a few more get punched in.

Operator

Yeah.

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

It is usually the analyst, and it is nothing overly controversial in most cases. Tim S usually goes through, not verbatim, usually prioritize which ones we see as the most important first. If there gets time at the end, then we jump into those.

Operator

Of course.

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

There's usually a topping and tailing of an intro that Tim S has done in the past. That's pretty much how we've done it.

Operator

Yep. Brent, just on that, are you happy for me to, I'll take my screen off, but happy for me to introduce the, thanks Simon, introduce the call, who's speaking, formal presentation, followed by Q&A. Over to you, Brent, to get things underway. Get to the end. Thanks, Brent. Bunch of questions. You're taking these in turn. I'll remind everybody how to actually ask the question. Not that they don't know. Go through them, get to the end, and then right at the very end, I'll throw back to you for closing remarks as well, if that works. Fantastic.

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

Yep. Perfect.

Operator

Great.

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

Can we just make a note that this recording, I think, goes to the cloud first and Tim snips it, and it doesn't get automatically distributed as an automated step after this. Just want to double-check that.

Operator

Yeah.

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

Usually because as soon as we let people in, it starts the recording, and people often transcribe it. We work on the basis that as soon as we let people in, that we're live.

Operator

Yep. Good. Sounds good. Simon, just in terms of the-

Simon Martin
CFO, Vitrafy Life Sciences

Yeah, I'm here.

Operator

in terms of the questions themselves, I'll direct them to

Simon Martin
CFO, Vitrafy Life Sciences

Adrian, let's just stop those calls to get started. The room, investors can hear what is going on.

Operator

Oh, we're not in practice mode. I thought we were. Okay. I was going to say, Brent, you direct the traffic.

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

We're 9:29. See people starting to flow in. Thank you for joining. We'll kick off in just a few minutes. We'll just allow a couple more minutes for people to access. We'll give it another 30 seconds, and then we'll start.

Operator

Good to go?

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

Yep.

Operator

Okay, so welcome everybody to Vitrafy Life Sciences Q1 FY 2027 quarterly update. We will go through a formal presentation, and we will leave plenty of room at the end for Q&A. I am sure we are all familiar how to ask questions, but just at the chat section at the bottom of your screen, you can add those questions. We will work through each of those in turn. I will let you do the introductions, Brent, but let me hand over to you to get things underway.

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

Thanks, Adrian. Thank you everyone for joining. As Adrian mentioned, a Q1 update. Following the full year results, which was only very recent, I am very proud of this update, actually. I think there has been a clear step-up and an acceleration from the business based on what we said we are going to do, which is a good place to be. I guess first and foremost, for us, one of the core objectives for the financial year was to build the partnerships in the U.S. blood space, in the civilian side in particular. I am very proud to share that we have got a couple more of those partners. We have signed our third in the quarter, which is one of the major blood collection networks in Versiti Blood Care. Importantly with that, it is actually for a different priority product across the blood space.

This one is in platelets, which is our first in the U.S. civilian market. That was a big milestone for the business. That also increases our exposure, and I will expend a little bit more time on this throughout the presentation, but what we are trying to capture is an increase in the percentage of market share across this civilian and military blood network. It was only a few months ago that we were very low on that percentage, and we are now up to approximately 17% of site exposure with the partners that we have. We also had our first partnership in cell and gene therapy, with Charter Medical, which is a CDMO based in the Carolinas. Something that we are really proud of.

Now where we sit as a business overall, we've got partnerships across cell and gene therapy, animal reproduction, red blood cells, blood and blood platelets across Army and civilian networks. So wide coverage and multiple shots on goal. To support that, what we also established in the quarter and announced at an event last week in Atlanta, Georgia, is the establishment of a new Scientific Advisory Board, which is made up of, in my opinion, world-class leaders and influencers in the space. That's not just in blood, that's in blood and cell and gene therapy, not just in the U.S.A., but more broadly as well, which I'll spend a little bit more time on in a moment. For that, we obviously need devices available and in market.

We did have nine devices built across the quarter and rolling off for use in both medical device applications, which I'll elaborate on shortly, as well as the supply for our partners in Vitalant, Hoxworth, Versiti, and Charter as well. With that, we've got a strong cash balance close to AUD 40 million, which Simon will spend a little bit more time on later in the presentation. So a strong quarter. Importantly, we are on track for, in the outlook, achieving our medical device registration this calendar year as well, which aligns with the original schedule too. Building on my first point about expanding the partnerships across the blood space. If I rewind a little bit and zoom out, what we're trying to achieve is widespread adoption and industry-wide change for the use of cryopreserved materials using Vitrafy's equipment.

We don't want to be a single point solution for one partner. We want to be an industry-wide change, and we're aware of some of the catalysts that are driving those changes across the red blood cell space and end-of-life technologies. So we're focused on securing a high percentage of market share across the U.S. civilian and military blood network. We're in October now. It was only in June that we had 0% of market capture. We're now proud to share that we have approximately 17% of that market capture, which has been a much accelerated pathway for us. That's in military and civilian across multiple blood applications. As you can see on the screen, Vitalant's focus is red blood cells, as is Hoxworth's.

Versiti's, which is the most recent announcement in the quarter is across platelets and plasma, and then we have a strong partnership, longstanding with the U.S. Army, for platelets, and they're supporting some of our medical device work currently in plasma as well. So that gives us access to approximately 179 of the fixed collection sites across the U.S.-focused collection centers, which is a significant increase from where we were only six months ago. We will focus and anticipate further growth in this space and expanding that percentage even wider, which is the gray box that you can see in that bar chart there. Expanding on my earlier point about the development of our Scientific Advisory Board. We recently went to, I'd say it's probably the biggest event in the U.S. across blood and biotherapies. It's called AABB.

It was in Atlanta last week, and at that event, Vitrafy hosted an event where we announced our Scientific Advisory Board, which are the participants that you can see on screen there. Importantly with that, they span across blood and biotherapies, in military and civilian applications. I just want to call out a couple of names there that are really quite important, as these are the people that will help guide and support the release of our scientific products and developments. That is going to be led by the Chair, Jose Cancelas, which is the second image you can see on that screen. Very influential in the market, and particularly in platelet innovations across blood and military networks. Jose has led the charge in that in many examples.

Also supporting that is the first image on the left, which is Pampee Young, who is the Chief Medical and Scientific Officer at the American Red Cross, which is obviously a major influence in the U.S. market and is a very large percentage of the U.S. blood market as well. The two images that you can see on the left is actually where we unveiled the Scientific Advisory Board in Atlanta. Vitrafy hosted a panel discussion where we had a very strong attendance with over 100 people, which is a lot for these types of events, where we spoke a little bit about the company and unveiled the Scientific Advisory Board, which you can see to the picture in the bottom left as well.

For us as a business, it is one thing to have a Scientific Advisory Board, but to get the caliber of people join the company really is quite significant for us. I observed a difference with engagement at AABB following the announcement and this event that you can see pictured here as well. Something that we are really proud of and have worked hard to achieve, and we do look forward to getting further support and direction and guidance from our Scientific Advisory Board in the future. Building on that, Vitrafy had a strong presence at AABB. I would say from a marketing perspective, this was the biggest investment we have made and the biggest presence that we had. We had the event that I just described, the announcement of the Scientific Advisory Board.

We also had a booth presentation, which is our second, and a strong team turnout there, which displayed both the Guardion device, and LifeChain as a software. The team did an excellent job with how they prepared and executed on that, and there was really strong engagement. That pipeline is really building and is getting quite strong, which is positive. To the image on the right, there was the release and the oral presentation of the platelets study that we completed with the US Army Institute of Surgical Research. The second phase of that study that you may recall, we shared the results of that in the recent months. That was presented at AABB for the first time, which was really positive discussion as well.

It's really interesting to see when a new opportunity is presented in the blood space and how the market responds to it, which I think that it went really quite well. That was also an achievement for the business at AABB. Where we sit from a marketing, brand awareness, pipeline development perspective is really in good shape, and we're feeling really comfortable and positive about that. Expanding on that slightly, we obviously, as I shared in the highlights, signed our first partnership with Charter Medical. Charter is really quite strategic for a number of reasons, and important. They are also a bag manufacturer of cryopreservation bags, which is important for Vitrafy's evolution, as everyone on this call is aware of. Importantly, they are a CDMO with quite a wide range of access to different cell and gene therapy drug developers and manufacturers as well.

They have access in the approximately 200 range, which Vitrafy intends to build relationships with those groups as well. Whilst Charter is important, they are only one of up to 300 CDMOs operating in the U.S. across approximately 1,800 different manufacturing centers as well. There is a wide opportunity for Vitrafy in that space to expand from where we're at with Charter as well. We are in the process at the moment of sending out equipment, both hardware and the software, to North Carolina, which is where Charter is located. We'll kick that off with some freeze-curve optimization for different materials in cell and gene therapy to really prove up that value proposition across a wide range of cell and gene therapy applications, which we look forward to kicking off in Q2.

With that, we've obviously got the animal work that's been continuing, working with IMV based in France. IMV focused on the bovine work, and we've been doing work in aquaculture. That testing has been continuing, and the optimization of that joint offering and generating that value proposition together remains ongoing, and we can see that program continuing through Q2. We should be getting some readout data and further progress towards the end of the calendar year in that space as well, which is progressing well. That's all based at IMV's facilities in L'Aigle, which is on the western side of France. For all of that to be successful, we obviously need equipment. We did put a forecast out of what devices we wanted to build. We have been having those roll off the production floor.

During the quarter, we had nine units that were built for uses with our partners, as well as supporting our medical device registration, which is obviously critically important. We have a further six that we've already shared that will be built and rolling off the floor in the second quarter as well to support some of those further works. Importantly, with the medical device registration, there are two buckets that we've spoken about in the past that are critical for that to be successful. The first is verification work, which is effectively the engineering component of that testing. A large percentage of that work is now complete, and we're feeling really confident with where that is at, which is a great place to be. Following the verification work, we then complete the validation work, which is effectively the biological testing on different materials.

We are starting with plasma, and plasma is a known frozen product, with standards that we are really comfortable and confident that we will be able to achieve. We are in the process right now of sourcing the plasma from multiple locations, setting up with the ISR, who will also be supporting that plasma testing, which keeps us on track for the medical device listing before the end of this calendar year. So first our second quarter of the financial year as well. Further to that we then have to have medical devices rolling off the floor. So we are looking at the first production fleet kicking off effectively in the second half of the financial year, in parallel ensuring that we are setting up our U.S. manufacturing stream to be online in the second half of 2027 as well. So a lot happening in that space.

A lot of parallel programs so that we can hit both all customer deployment, verification, validation, medical device listing, U.S. manufacturing, and ramping that up as well. So we have got capability to increase production where required for the demand side too. I will hand it over to Simon now to go through the financials. Who is on mute?

Simon Martin
CFO, Vitrafy Life Sciences

He is on mute. Thank you, Brent. Hopefully reasonably clear here. We ended the quarter with AUD 38.3 million net operating cash outflow of AUD 4.9, so an average burn of AUD 1.9 on a gross basis. Got just under eight quarters of funding based on that. You can see more importantly on the right more of our costs going into manufacturing and marketing. We are still putting that through the P&L because they still are pre-medical device, and that spend will continue as we have flagged in prior quarters. So still in a very strong position, good runway through to 2028 still, and feeling good about all the activities we have got on the go, and well-funded. Back to you, Brent.

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

Thanks, Simon. With that, there is obviously the outlook. So we shared at the full year results what we aim to achieve over the financial year, and one quarter in, feeling in really good shape with what we have achieved so far, but there is much more to come. Obviously, that is led by the FDA medical device listing, which we are expecting before the end of calendar year. We announced recently that I will be relocating to the U.S. That includes setting up a U.S. headquarters in Colorado, which we are close to doing as well, and expecting that to build out. Importantly, converting the pipeline opportunities across both the blood and CGT network in military and civilian uses. Then into next year, we keep building out the medical device manufacturing, setting up U.S. manufacturing, and having that in production.

As well as the recent announcement of the new CFO starting in February 2027, who will be based in Australia, and support a lot of the Australian operations as well. A lot of activity, a lot to look forward to. Very proud of what we've achieved in a short amount of time, but still lots more to come. I will pause there, hand it back to Adrian, and thank everyone for their time.

Operator

Thanks, Brent. Sorry, just unmuting. Just a reminder those on the line to ask questions, just a Q&A at the bottom of your screen, and we can work through each of them in turn. We've got a number, Brent. Let me just start with the first one. How does CGT commercialization evolve from here, and what doors can Charter Medical open for Vitrafy?

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

Good question. I'll start with the second part, the doors that Charter Medical can open. It's a very tight-knit community, CGT, that I've observed, and relationships are really quite important. Charter Medical have strong relations with a number, multiple hundreds of different developers and biotech companies. We intend to firstly generate value and data with them, and also engage with the network of biotech and drug developers that Charter Medical have. Expanding on that with the first part of your question about unlocking contracts with them, I think was what you were asking. Besides getting the data to keep proving up the value proposition, which is a continual, we keep doing that to keep strengthening our value proposition in the space. We do believe that we can execute commercial contracts in the near term in that space.

Medical device registration is not mandatory in the area, but we do need to have a Design History File, which is kind of a big component of the medical device listing that would go into some of these work streams. Having it is really important from a marketing perspective, but we don't need it to enable commercial contracts in the space. What we're working towards right now is execution of commercial contracts in CGT, and Charter Medical's really quite important for a number of reasons that I've outlined before. First and foremost with them, though, we've got to generate the data, but that doesn't prevent us from signing commercial contracts with others.

Operator

That's great. Thanks, Brent. Next question. With respect to the end 2026 target for U.S. medical device listing, what verification and validation work remains, and which outstanding tasks present the greatest risk to achieving that timetable?

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

Yeah. There's an irony in this question, actually, and that is one of the problems we're trying to solve is the availability of blood. The risk that I foresee right now to hit that timeline is getting enough blood to test as part of our validation work. From a risk perspective, I would say that having the supply of blood in the volumes that we need is the main risk to hit the timeline. The tasks that are going on across verification and validation span everything from electrical safety and performance of the equipment, that's on the verification side, those types of tests. On the validation side, it's testing that the biological material is achieving its quality standards as per the FDA requirements for that specific use.

The verification work, the engineering piece, a large percentage of that is now complete or close to complete, and we're feeling in good shape with where that's at. That then flows into the validation work, which we're getting ready to start with the Institute of Surgical Research, who'll be completing some of that initial testing on plasma as well. A large percentage of that work is de-risked, and a lot of it's progressed, and we're now moving into the biological testing, where the risk I shared is primarily around access and supply to blood to be able to do what we need to do in the volumes that we need to do them in.

Operator

Thanks, Brent. A couple of questions on milestones. Let me combine the one more general one and one more specific one, but you'll get the point here. Looking ahead six to 12 months, what milestones should investors judge Vitrafy against? More specifically, what are the key milestones for establishing U.S. manufacturing, and how should we think about the operational and gross margin upside?

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

Okay, I'll try to go start to finish on that, but please jump in if I miss it or butcher what you've asked. Starting with the milestones. For those that have read the pack, the last slide has a bit of an outlook, and I would say that that summarizes what we're really trying to focus on as a business. First and foremost, in the next six months, we want to have medical device registration. That's a big one, and we are on track with achieving that milestone. With that comes the unlocking of further commercial activity in the U.S. blood space across civilian and military. We are really focused on achieving the medical device registration. What else to look for from an investor's perspective? Something that we're trying to really focus on is building the percentage of market share across the blood market, civilian and military.

There are logos that are displayed within the presentation, which make up a large percentage of that market. So trying to build that percentage, which was zero six months ago. It's 17% approximately now, and we want to make that much further north and above 50% within the next six to 12 months as well. So that will be something to measure and assess us on, how much of that percentage we capture across the blood network. That's a really strong lead indicator as to achieving our goals. Beyond that, we want to set up not just U.S. manufacturing, which was the last part of your question, but also the right team and structure to be able to go with it.

Headquarters, as I mentioned, in the process of being executed and building out that team further to be able to support all of that U.S. manufacturing customer success in field. Our U.S. team that we've been building has been primarily focused on sales and marketing and a little bit of commercial operations, and now we want to build that further to be effectively full U.S. operation across all the different departments that we require to support not just the manufacturing work, but the in-field customer work too. In preparation, and the preparation that we need to do for U.S. manufacturing, a big part of it is the team that we mentioned.

We did appoint a COO, who starts in a couple of weeks as well, who's got a very strong background in medical device manufacturing for very large companies as well, who will be an excellent addition to support that U.S. manufacturing piece. We just want to make sure that we can set up manufacturing made in America, continuous production rather than single small batches, which is currently what we're doing at the moment. I'll let Simon speak to the potential economics of that as we move from batch manufacturing in Australia to then higher volume continuous in the U.S.

Simon Martin
CFO, Vitrafy Life Sciences

Thanks, Brent. Just building on that, I think the question was also touched on margins and operations. Yes. Our goal has always been to ensure we're made in America. That's just a necessity. We are driving towards a continuous flow of manufacturing rather than batch, as Brent pointed out. There are three benefits to that. One is clearly, we are focused on a high quality output. It's a medical device, it must be. You run less risk of error if you're tooling up and down on a batch basis. So quality is key. Continuous throughput is important for that. The other obvious factor is cost. We can drive costs further down, and that's the goal. So that's what we're targeting.

The third piece is to ensure that we are as close to customer as possible, and manufacturing in the U.S. alongside design and science is really important. There are often variations that might be required, for instance, to the racking, and having the team sitting alongside that makes it really important. Hence the shift to the U.S.

Operator

That's great, Simon. Very clear. Thank you. You'd made mention of some of this next question in your slide when you talked about the number of quarters left with the current cash balance. But the specific question, with AUD 38.3 million in cash and term deposit and expenditure expected to increase, what funding runway do you anticipate under the current operating plan, and which development and commercial milestones should that cash support?

Simon Martin
CFO, Vitrafy Life Sciences

Yes. That funding runway is in our current outlook and in line with the raise we did back in June. Should see us well into 2028, and supports an initial fleet of circa 100 medical devices next year. Now, clearly, a quality problem will be if we need to flex up because of demand, which we hope will be the case, then we'll need to revisit that. We need to moderate expectations to ensure we get really good delivery, and that's part of building our delivery, our commercial ops team, and the science alongside it. But we're fairly comfortable into 2028 and are constantly looking at how we can ensure that we utilize that capital to the best returns in the short term.

Operator

Great. Thanks, Simon.

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

On-

Operator

Sorry, did you want to make a comment, Brent?

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

Just calendar versus financial on 2028.

Operator

Sorry. Calendar. Yes.

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

Calendar.

Operator

End of calendar 2028. Yeah.

Good calibration. Just next one. How will the agreement with Charter Medical create commercial opportunities with cell gene therapy developers, and what milestones would demonstrate that this relationship is progressing from technology evaluation towards revenue?

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

Key part for CGT for us is generation of data, and it is different to the blood world in many ways. One difference is the dependence on data to make decisions, and we have generated some really strong data in the past. In T-cells in particular. That will be presented at a conference in December as well, just as a bit of a heads-up, some of the T-cell work we have been doing. But generation of data with Charter is an important piece to the puzzle, and we will work through that in an expedited way. Back to my earlier point, we do not see that preventing us from commercial agreements in CGT with others as well. Charter is important for a number of reasons. The data is one of them. Converting that into a commercial contract after we generate that data is another important piece.

Also the access that they will provide is a really important strategic part of that puzzle, too. So generation of data is the first point, and then from there we could see the conversion. That should move in an expedited fashion.

Operator

That's great.

Simon Martin
CFO, Vitrafy Life Sciences

Also another piece is that they are a bag manufacturer, and the ability to work with them on potential solutions for more general use is something that's an added benefit. We haven't gotten there yet, but they are keen, and we are keen to explore that.

Operator

Yeah. Thanks, Simon. Good point. Thanks, Brent. We've exhausted the audience, so obviously, all of the details were covered as we expected. Back to you for any kind of closing remarks.

Brent Owens
Co-Founder, Managing Director, and CEO, Vitrafy Life Sciences

No, thank you, everyone, for joining. Any further questions, please feel free to reach out. Happy to expand further and have further catch-ups if required. Again, it feels to me that since the full year, we have accelerated, and hopefully, that's flowing through as well. But we're feeling in really good shape with what we're building, how we're building, and how we're executing on what we said we're going to do. So thank you for the support, and the ongoing support. Really very much appreciate it, and look forward to some near-term catalysts as well.

Operator

That's great. Thanks, everybody.